New hope for rare lung cancer mutations: targeted pill tested after surgery

NCT ID NCT05546866

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study tests whether the targeted drug osimertinib can help prevent lung cancer from returning after surgery in patients with uncommon EGFR gene mutations. About 51 adults with stage IB-IIIB non-small cell lung cancer will take an 80 mg pill daily for up to 3 years. Researchers will track how many remain cancer-free at 2 and 3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osimertinib (a targeted cancer pill)
What this could lead to: If successful, this could provide an effective post-surgery treatment option for lung cancer patients with uncommon EGFR mutations, potentially delaying or preventing cancer return.
What could go wrong: This is a small, early-phase (Phase 2) study with only 51 participants and no comparison group. The results may not apply to all patients, and the drug has known side effects like rash and diarrhea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Research Site

Beijing, 100730, China
Research Site

Chengdu, 610000, China
Research Site

Chengdu, 610041, China
Research Site

Fuzhou, 350011, China
Research Site

Guangzhou, 510080, China
Research Site

Kunming, 650118, China
Research Site

Ningbo, 315010, China
Research Site

Shijiazhuang, 050051, China
Research Site

Suzhou, 215006, China
Research Site

Tianjin, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.